Index

A
Abiraterone acetate, 403–404
Acid phosphatase, 51
Active surveillance (AS)
autopsy studies, 216–217
cancer vs. overdiagnosis, 215, 216
clinical tools
biopsy sampling error, 218
focal therapy, 220
follow-up calender, 219
general linear mixed model, 218
PEAT, 218
psychological effects, 219
START trial, 219–220
components, 217
ERSPC, 215–216
future perspectives, 220–221
latent cancers, 215
saturation prostate biopsy role in, 188–189
Adipokines, 132
Adiponecin, 132
Adjustable balloons, 327–328
ADT. See Androgen deprivation therapy (ADT)
AdVance™ sling suspension, 331–332
Agent Orange, 9
Alpha-methylacyl-CoA racemase (AMACR), 156
5 Alpha-reductase inhibitors (5ARI)
BPH, clinical trials, 144–145
dihydrotestosterone, 144
dutasteride, 147–149
finasteride, 145–147
American Cancer Society (ACS), 40
American Urological Association (AUA), 39–40
Androgen deprivation therapy (ADT), 172
cardiovascular disease
AHA guidelines, 396
aspirin and statins, 396
CaPSURE database, 392
cardiovascular mortality, 392, 395
CHD, 395
GnRH agonist, 390, 392
lifestyle interventions, 395–396
population-based database analyses, 390, 391
post-hoc analyses, 392–394
insulin resistance and diabetes mellitus
hormone-naive prostate cancer, 387
hypogonadism, 387
leuprolrelin acetate, 386
low testosterone levels, 386
oral glucose tolerance tests, 386
population-based study, 387–388
prevalence and risk, 386
lipid alterations, 389–390
metabolic syndrome, 388–389
osteoporosis
bisphosphonates, 381–382
bone mineral density loss, 381
hip and vertebral fracture, 381
practical recommendations, 383–384
RANKL-targeted therapy, 383
selective estrogen receptor modulators, 382–383
with radiation therapy
Canadian RCT, 288
clinical outcomes, 286
EORTC 22863, 287
EORTC 22961, 288–291
optimal duration, 287
RTOG 85-31, 286
RTOG 86-10, 287
RTOG 92-02, 288
Trans-Tasman Oncology Group 96.01
RCT, 287–288
sarcopenic obesity
BMI, 384
body composition, 384
CT scans, 385
fat and lean body mass, 385
fat mass accumulation, 384–385
prevalence, 384
resistance training, 385–386
testosterone, 384
Androgens
and androgen receptor
cancer development, 118–119
coregulatory proteins recruitment, 117
CRPC (see Castrate-resistant prostate cancer)
prostate physiology, 118–119
structure, 117
testosterone production, 117
Argus, 330
Artificial urinary sphincter (AUI), 324, 333–335
Asymptomatic prostatic inflammation, 103
Atypical glands suspicious for cancer (ATYP), 160–161

B
Benign prostatic hyperplasia (BPH)
androgen receptor, 118
chemoprevention, 144–145
Benign PSA (BPSA), 15
Beta-emitting radiopharmaceuticals. See Bone metastasis
Bicalutamide, 402
Bilateral orchiectomy, 363
Biochemical recurrence (BCR)
androgen deprivation therapy, 354–355
antiandrogens, 355
chemotherapy, 355
diagnostic studies
bone scan, 349–350
computerized tomography, 350–351
magnetic resonance imaging, 350
ProstaScint, 351
prostate biopsy, 351
PSA, prognosis, 348–349
radical prostatectomy, 347–348
radiotherapy, 348
with brachytherapy, 353–354
with cryotherapy, 353
with radical prostatectomy, 352–353
Biomarkers and PSA, 218, 221
acid phosphatase, 51
CaP specificity
annual growth rate, 53–54
PCA3 and proPSA, 52–53
concentrations, 52, 53
ETS gene fusions (see ETS gene fusions)
FDA approvals, 51–52
future perspectives, 65
needs for, 52
PCA3 gene
biopsy nomogram, 64–65
discovery and early characterization, 60
feasibility, 60–61
future prospects, 66
multivariate logistic model, 64, 65
PCPT risk calculator and, 64
TMA assay (see Transcription-mediated amplification (TMA) assay)
proPSA
Beckman Coulter Hybritech p2PSA
immunoassay, 57
Epstein criteria and Gleason score, 59
patient management, 59
phi and prostate cancer detection, 58
receiver operator characteristic curves, 57–58
uses, 59–60
composition, 55
isoforms, 55
phi derivation, 55–56
prostate cancer detection, 54
serum levels, 54
tissue and microplate studies, 56
prostate tissue
EPCA, 72–73
GSTP1 methylation, 72
Ki-67, 71–72
p27 and PSCA, 73
tumor shrinking volume, 52, 53
Body mass index (BMI), 7, 127
Bone metastasis
beta-emitting radiopharmaceuticals
combination therapies with, 415–417
phosphorous 32, 413–414
Rhenium 186 and Rhenium 188, 415
Samarium 153, 414–415
Strontium 89, 414
lytic activity, 413
BPSA. See Benign PSA (BPSA)
Brachytherapy, 264, 353–354
health-related quality-of-life, 311–312
Kaplan–Meier estimate
biochemical relapse-free survival, 264
clinical relapse-free survival, 265
overall survival, 265, 266
prostate cancer-specific survival, 266, 267
toxicity, 267, 268

C
Cabazitaxel, 407–408
Cancer of the Prostate and Brain (CAPB), 81
Candidate gene studies. See Hereditary prostate cancer (HPC)
Carboplatin, 407
Castrate-resistant prostate cancer (CRPC)
androgen receptor, 401–402
activation, growth factor and cytokine, 120
androgen deprivation, 120–121
anti-androgenic activity, 120
AR mRNA, 119
coactivator protein modification, 120
future aspects, 121
mechanisms, 119
somatic mutations, 119–120
truncated variants, 120
chemotherapy, 408
docetaxel, 407–408
mitoxantrone, 406
taxanes, 406–407
hormonal manipulations, 408
adrenal inhibitors, 402–403
Index

androgen inhibitors, 403–404
antiandrogen inhibitors, 404–405
antiandrogen withdrawal, 402
estrogenic therapies, 403
secondary, 402
immunotherapy in, 404

Chemoprevention, 143–144
classification, 143
five alpha-reductase inhibitors
BPH, clinical trials, 144–145
dihydrotestosterone, 144
dutasteride, 147–149
finasteride, 145–147
primary vs. secondary prevention, 144
vitamins and nutrients
aspirin and folate, 150
dietary factors, 149
hazard ratio, 150
phytoestrogens, 150–151
selenium and vitamin E, 149–150
zinc, 150

Chemotherapy, 403
biochemical recurrence, 355
bone metastasis
Samarium 153, 416
Strontium 89, 414, 415
castrate-resistant prostate cancer, 408
docetaxel, 407–408
mitoxantrone, 406
taxanes, 406–407

Chronic myelogenous leukemia (CML), 66–67
Chronic prostate inflammation, 103–105
COLD (Cryo On-Line Data) registry, 235
Color Doppler TRUS (CDUS), 191–192
Combination androgen blockade (CAB), 370–371
Complexed PSA (cPSA), 15
Contrast-enhanced color Doppler (CECD), 192
Cryo Online Data Registry (COLD), 312
Cryotherapy
health-related quality-of-life, 312
post-radiotherapy recurrence, 353

Cyclo-oxygenases (COXs), 110
Cytochrome P (CYP)17, 403

D
Diabetes mellitus, ADT
hormone-naive prostate cancer, 387
hypogonadism, 387
leuprorelin acetate, 386
low testosterone levels, 386
oral glucose tolerance tests, 386
population-based study, 387–388
prevalence and risk, 386
Diet and nutrition
calcium and vitamin D, 136
carbohydrates, 135
dairy products, 136
dietary fat, 134–135
energy intake and balance, 133–134
influences, 133
lycopene, 137
red meat consumption, 135–136
selenium and vitamin E, 137
soy and isoflavones, 136–137
weight loss, 133–134
Diethylstilbestrol (DES), 121, 122
Digital rectal examination (DRE), 15, 16
Dihydrotestosterone (DHT), 118
Distant metastasis failure survival (DMFS), 281–282
Docetaxel-based chemotherapy
cabazitaxel, 407–408
carboplatin, 407
mitoxantrone and prednisone, 407
Dose-escalated radiation therapy
clinical trials
Loma Linda University Medical Center and MGH, 282–283
McMaster University Brachytherapy, 283
M.D. Anderson dose-escalation study, 282
Memorial Sloan-Kettering Cancer Center, 283–284
disease-free survival, 281
distant metastasis failure survival, 281–282
GI and GU toxicity, 284
LLUMC/MGH trial, 284
McMaster University plus brachytherapy boost study, 285
M.D. Anderson trial, 284
MSKCC toxicity data, 285
RTOG 94-06, 285

Duloxetine, 327–328
Dutasteride, 146–149

E
Early prostate cancer antigen (EPCA), 72–73
ePBx. See Extended biopsy (ePBx)
Epstein–Barr virus (EBV), 107
ERSPC. See European Randomized Study of Screening for Prostate Cancer (ERSPC)
Erythroblast transformation-specific (ETS) gene fusions
clinically aggressive prostate cancer, 69–70
CML, 66–67
COPA, 67
DNA microarrays, 67
eye diagnosis, 68–69
multifocality, 68
potential applications, 70
prevalence, 68
schematic representation, 67
TMPPRSS2, 67

Estrogens and estrogen receptor
cancer genesis and progression, 121
diethylstilbestrol, 121, 122
isoforms, 121–122
selective ER modulators, 122
prostate inflammation, 107
European Association of Urology (EAU), 40
European Randomized Study of Screening for Prostate Cancer (ERSPC), 19–21, 31–32, 34
Evidence-based tumor prediction, 201–202
Expanded prostate cancer index composite (EPIC) instrument, 300
Extended biopsy (ePBx)
  apical cores, 183–184
  core number, 184–185
  eleven-core biopsy scheme, 183
  five-region biopsy scheme, 182
  laterally directed cores, 183
  ten-core biopsy scheme, 182
  transitional zone, 184
  twelve-core biopsy scheme, 183
External beam radiation therapy (EBRT), 243, 264
  See also Radiation therapy vs. brachytherapy, 254
  genitourinary and gastrointestinal toxicity, 268
  health-related quality-of-life, 309–311
  locally advanced prostate cancer
    EORTC 22863 trial, 252
    EORTC 22961 trial, 253
    RTOG 85-31, 253
    RTOG 85-31 randomized trial, 253
    RTOG 92-02 randomized trial, 253
    RTOG 86-10 trial, 252
    Trans-Tasman Radiation Oncology Group 96-01 trial, 252–253
  outcomes of, 248
    biochemical relapse, 249
    clinically localized prostate cancer, 250–252
    locally advanced prostate cancer, 252–254
    PSA bounce phenomenon, 249
  overall survival, 265
  postoperative, 256–259
  principles of, 244
  vs. radical prostatectomy, 254
  sequelae of, 254–256
  toxicity, 267
Extra-capsular extension (ECE), 230
Extraprostatic extension (EPE), 166–167

F
Finasteride
  Proscar Long-Term Efficacy and Safety Study, 145
  Prostate Cancer Prevention Trial
    clinical criteria, 145
    economic cost, 147
    HGPIN, 147
    high grade prostate cancer, 145–146
    PSA detection, 147
    sampling density biopsy, 146–147
    sexual function, 147
    side effects and morbidity, 147
  First repeat biopsy (fRBx), 188
  Flutamide, 402
  Focal therapy
    future aspects, 238–239
  hemi-cryoablation
    cancer-control and complication rates, 235, 236
    clinical outcomes, 237
    COLD registry, 235
    HIFU trial, 237
    hidden lesions, 237–238
    patient selection, 232–233
    prostate biopsy, 233–234
    prostate imaging, 234–235
    surveillance, 235
  unilateral hemi-ablation model
    bDFS rates, 230
    extra-capsular extension, 230
    index tumor, 226–229
    Kaplan-Meier recurrence-free survival plots, 228, 229, 231
    lymph nodes metastases, 232
    PSA failure rates, 230
    satellite lesions, 232
    small-volume PCAs, 230–231
    tumor volume, 231–232
    unilateral lesions frequency, 227
  Freedom from biochemical failure (FFBF), 250
  Functional Assessment of Cancer Therapy-Prostate (FACT-P), 303

G
Gene fusion. See Erythroblast transformation-specific (ETS) gene fusions
Genitourinary toxicity, 268–269 See also Dose-escalated radiation therapy
Genome-wide association studies (GWAS), 88–89
Gleason score (GS) grading system, 243
  biopsy vs. radical prostatectomy, 158
  histologic patterns, 156–157
  modified
    pattern interpretation, 157
    primary, secondary, and tertiary pattern, 158
    tumor variants, 157–158
  prognostic value, 158–159
  Glutaraldehyde cross-linked (GAX) collagen, 336

H
Health-related quality-of-life (HRQOL)
  after brachytherapy, 311–312
  after external beam radiotherapy, 309–311
  after radical prostatectomy, 308–309
  cryotherapy, 312
  high intensity focused ultrasound, 312–313
  historical perspective, 298–299
  instruments
    AUA-SI/IPSS, 300
    Expanded Prostate Cancer Index Composite, 300, 302–304
    Functional Assessment of Cancer Therapy-Prostate, 303
    function vs. bother, 299
    IIEF/SHIM, 300, 302
Memorial Anxiety Scale for Prostate Cancer, 303, 304
minimally important difference, 299–300
Prostate Cancer QOL questionnaire, 302
Prostate Cancer Symptom Index, 303
prostate module (PR25), 303
questionnaire development, 299
UCLA-PCI, 302

Hereditary prostate cancer (HPC)
candidate gene studies
BRCA1 AND BRCA2, 85–86
CHEK2, 87–88
hOGG1 and MIC-1, 87
linkage disequilibrium, 84–85
PON1, 86–87
ethnic variation, 79
family history, 79
GWAS
β-microsemionprotein gene, 89
cGEMs, 88
deCODE genetics, 88–89
MYC oncogene, 89
heterogeneity, 90
linkage analysis, 80
chromosome 16q23, 82
HPC2, 82–83
HPC20 and HPCX, 83
HPC1/RNASEL, 80–81
macrophage scavenger receptor 1, 81–82
PCAP and CAPB, 81
tumor aggressiveness, 83–84
High grade prostatic intraepithelial neoplasia (HGPIN)
ADT, 172
ATYP, 161
ER receptor, 122
finasteride, 47
incidence, 161
prostate biopsy, 161–162
selenium, 150
SPBx, 187
High intensity focused ultrasound (HIFU)
hemi-ablation, 237
HRQOL, 312–313
High-molecular-weight cytokeratin (HMWCK), 156
HPC. See Hereditary prostate cancer (HPC)
Human glandular kallikrein-2 (hK2), 14
Human papillomaviruses (HPVs), 105

IGF-I. See Insulin-like growth factor-I (IGF-I)
Image-guided radiation therapy (IGRT), 245
Immunohistochemistry (IHC), 155, 156
Injection therapy, PPI, 334–335
advantages, 337
autologous fat, 336
collagen, 336
Dondren, 335–336
drawbacks, 337
mild-moderate SUI, 336–337
paraffin and teflon, 335–336
retrograde and antegrade delivery, 337
vulcanized silicone rubber particles, 336
Insulin, 132
Insulin-like growth factor-I (IGF-I), 7, 8, 132
Intact PSA (iPSA), 15
Intensity modulated radiation therapy (IMRT), 245
International Society of Urologic Pathology (ISUP), 157
Intrarectal local anesthesia (IRLA), 178
Intrinsic sphincter deficiency (ISD), 321
Isoflavones, 136–137

K
Kaplan–Meier estimation
biochemical relapse-free survival, 264
clinical relapse-free survival, 265
overall survival, 265–266
Ketoconazole, 402–403
Ki-67, 71–72

L
Leptin, 132
Linkage disequilibrium (LD), 84
Locally advanced prostate cancer.
See External beam radiation therapy (EBRT)
Low-and intermediate-risk prostate cancer
PROSQA study, 269
treatment efficacy
biochemical failure, 263–265
biopsy Gleason score, 263
clinical failure, 265
overall survival, 265–266
pre-treatment PSA, 263
prostate cancer-specific survival, 266, 267
toxicity, 265–269
Luteinizing hormone-releasing hormone (LHRH), 117, 119
Lycopene, 137
Lymphovascular invasion (LVI), 169

M
Macrophage scavenger receptor 1 (MSR1), 81–82
Male slings. See Urethral slings, PPI
Margin of resection (MOR), 167–169
Memorial Anxiety Scale for Prostate Cancer (MAX-PC), 303, 304
Memorial Sloan-Kettering Cancer Center (MSKCC), 250
Men’s Eating and Living (MEAL) study, 151
Metagram, 209, 210
Metastatic prostate cancer, 173–175
androgen deprivation, 362–363
adrenal steroidogenesis inhibitors, 367
anemia, 369
antiandrogen therapy, 366–367
bilateral orchiectomy, 363
chemoendocrine therapy, 372–373
early vs. delayed, 372
Metastatic prostate cancer (cont.)
estrogens, 367
hot flushes, 368
intermittent, 371–372
LHRH agonists, 363–365
LHRH antagonists, 365–366
metabolic syndrome, 369–370
osteoporosis, 368–369
combined androgen blockade, 370–371

Osteoporosis, ADT
bisphosphonates, 381–382
bone mineral density loss, 381
hip and vertebral fracture, 381
practical recommendations, 383–384
RANKL-targeted therapy, 383
selective estrogen receptor modulators, 382–383

P
Pathologic stage (pTNM), 170, 171
PBx. See Prostate biopsy (PBx)
PCA. See Prostatic adenocarcinoma (PCA)
PCa. See Prostate cancer (PCa)
PCA3. See Prostate cancer gene 3 (PCA3)
PCPT. See Prostate Cancer Prevention Trial (PCPT)
Pelvic floor muscle training (PFMT), 326–327
Percent tumor involvement (PTI), 232
Perineural invasion (PNI), 159–160
Peri-prostatic nerve block (PPNB)
infiltration sites, 178
lidocaine injection, 180
Mount Everest sign, 179
oral medications, 179
2-Amino-1-methyl-6-phenylimidazopyridine (PhIP), 108
Phosphodiesterase type 5-inhibitors, 328
Phosphorous 32, 413–414
PIN. See Prostatic intraepithelial neoplasia (PIN)
PLCO. See Prostate, Lung, Colon and Ovary Cancer Screening Trial (PLCO)
PNBX. See Prostatic needle biopsy (PNBX)
Polyunsaturated fats (PUFAs), 134–135
Post-prostatectomy incontinence (PPI)
clinical evaluation, 323–324
counseling process, 321
detrusor instability, 320
factors affecting
bladder neck preservation, 323
nerve-sparing operation, 321–323
neurovascular preservation, 322
preoperative factors, 321
puboprostatic ligaments maintenance, 322
surgical technique, 321
urethral length, 322–323
vs. preoperative continence, 322
rhabdosphincter reconstruction, 323
sphincter dysfunction, 320–321
time-dependent course, 321
tip-sparing prostatectomy, 323
treatment
artificial urinary sphincter, 324
balloon-type mechanisms, 325
of bladder dysfunction, 327
conservative, 325
gene therapy, 329
historical perspectives, 324–325
injection therapy (see Injection therapy, PPI)
male slings (see Urethral slings, PPI)
modern AMS 800™, 325
PFMT and biofeedback, 326–327
ProACT system, 325, 327–328
regenerative therapy, 328–329
of sphincteric dysfunction, 327–328
Power Doppler imaging (PDI), 192
PPNB, See Peri-prostatic nerve block (PPNB)
Predisposing for CAncer of the Prostate (PCAP), 80, 81
ProACT system, 325, 327–328
Proliferative inflammatory atrophy (PIA), 103, 105
Propionibacterium acnes, 105
Proprostate-specific antigen (ProPSA)
automated assay studies, 57–60
Beckman Coulter Hybritech p2PSA
immunoassay, 57
Epstein criteria and Gleason score, 59
patient management, 59
phi and prostate cancer detection, 58
receiver operator characteristic curves, 57–58
uses, 59–60
composition, 55
isoforms, 55
phi derivation, 55–56
prostate cancer detection, 54
serum levels, 54
tissue and microplate studies, 56
Proscar Long-Term Efficacy and Safety Study (PLESS), 145
Prostate biopsy (PBx)
anesthesia, 178
ePBx (see Extended biopsy (ePBx))
evolution, 177
modification, 181
PPNB
infiltration sites, 178
lidocaine injection, 180
Mount Everest sign, 179
oral medications, 179
pre-biopsy preparation, 177–178
sPBx (see Saturation prostate biopsy (sPBx))
standard sextant biopsy, 181
TP biopsy (see Transperineal prostate (TP) biopsy)
TRUS probe configuration
CDUS, 191–192
CECD, 192
end-fire probes, 193, 194
RTE, 192
side-fire probes, 192–193
Prostate cancer (PCa)
active surveillance (see Active surveillance)
androgen deprivation therapy (see Androgen deprivation therapy)
androgens (see Androgens)
biochemical recurrence (see Biochemical recurrence)
biomarkers (See Biomarkers and PSA; Prostate-specific antigen)
brachytherapy (see Brachytherapy)
castrate-resistant (see Castrate-resistant prostate cancer)
chemoprevention (see Chemoprevention)
diet and nutrition
calcium and vitamin D, 136
carbohydrates, 135
dairy products, 136
dietary fat, 134–135
energy intake and balance, 133–134
influences, 133
lycopene, 137
red meat consumption, 135–136
selenium and vitamin E, 137
soy and isoflavones, 136–137
weight loss, 133–134
epidemiology, 1–4
estrogens (see Estrogens)
focal therapy (see Focal therapy)
health-related quality-of-life (see Health-related quality-of-life)
hereditary (see Hereditary prostate cancer)
inflammation (see Prostate inflammation)
low-and intermediate-risk (see Low- and intermediate-risk prostate cancer)
metastasis (see Metastatic prostate cancer)
nomograms (see Nomograms)
obesity (see Obesity)
prostate biopsy (see Prostate biopsy)
radiation therapy (see Radiation therapy)
radical prostatectomy (see Radical prostatectomy (RP))
risk factors
age, 4–5
Agent Orange, 9
environment/diet, 7–8
genetics, 5–7
infection/inflammation, 8
infertility, 9
race and ethnicity, 4–5
radiation and tobacco, 9
vasectomy and ejaculatory frequency, 9
screening, 9–10 (see also Prostate cancer screening)
Prostate cancer gene 3 (PCA3)
biopsy nomogram, 64–65
discovery and early characterization, 60
feasibility, 60–61
future prospects, 66
multivariate logistic model, 64, 65
PCPT risk calculator and, 64
TMA assay (see Transcription-mediated amplification (TMA) assay)
Prostate Cancer Intervention Versus Observation Trial (PIVOT), 39
Prostate cancer markers. See Biomarkers and PSA
Prostate cancer mortality (PCM), 130–131
Prostate Cancer Prevention Trial (PCPT), 118, 145–147
Prostate Cancer QOL questionnaire, 302
Prostate cancer screening
adverse events
ERCPC screening protocol, 37–38
PLCO study, 38
clinical practice
American Cancer Society, 40
American Urological Association, 39–40
European Association of Urology, 40
life expectancy, 44–45
Prostate cancer screening (cont.)

“proactive” counseling approach, 45
recommendations, 39–41
USPSTF, 40–41
early detection effectiveness, 38–39
mortality, 37
outcomes and future aspects, 45–46
prevalence, 25
PSA
diagnosis and treatment, 25–26
limitations, 26–28
thresholds and benefits, 41–43
randomized controlled trials
characteristics and methodological quality, 31, 33
ERSPC, 31–32, 34
PLCO study, 34–36
risk ratio, 31, 32
SPCG-4 study and PIVOT, 39
Treatment-induced harms, 45–46
USPSTF
certainty level, 29
evidence quality, 28–29
net benefit, 29–30
recommendation statements, 30
Prostate Cancer Symptom Index (PCSI), 303
Prostate Health Index (phi), 53
Prostate inflammation
chronic or recurrent
immune cells, 105
PIA and PIN lesions, 105
prostate epithelial damage, 104–105
prostatitis, 103–104
PSA screening, 104
epithelial damage
diet, 108–109
elevated serum PSA, 106
“hit-and-run” infection, 106–107
human papilloma viruses, 106
Propionibacterium acnes, 106
sex steroid hormones, 107
sexually transmitted infections, 106
mechanism, 103
molecular genetics and pathogenesis, 109–110
prevention
aspirin, 110
NSAIDs, 110
statin drugs, 111
Prostate, Lung, Colon and Ovary Cancer Screening Trial (PLCO), 20, 21, 34–36
Prostate module (PR25), 303
Prostate specific antigen (PSA), 243
Prostate-specific antigen (PSA), 215–216
See also Prostate-specific antigen; Biomarkers and PSA
biosynthesis and molecular forms, 14
complexed, 15
derivatives
age-specific ranges, 17
f/t PSA and PSAD, 18
PSADT, 19–20
PSAHL, 20
PSAV, 18–19
factors affecting, 15–16
function, 14
history, 13
molecular structure and isoforms, 13–14
precursor form of, 14–15
prostate cancer detection
ERSPC study, 20–21
PLCO, 20
sensitivity and specificity, 16–17
Prostate-specific antigen density (PSAD), 18
Prostate-specific antigen doubling time (PSADT), 19–20
Prostate-specific antigen half life (PSAHL), 20
Prostate-specific antigen velocity (PSAV), 18–19
Prostate stem cell antigen (PSCA), 73
Prostatic adenocarcinoma (PCA)
ADT, 172, 174
diagnostic methods, 153
distant metastasis, 173–175
lymph node involvement, 170–171
PNBX (see Prostatic needle biopsy (PNBX))
radiation therapy, 172, 173
RP (see Radical prostatectomy (RP) specimens)
Prostatic Evasive Anterior Tumours (PEAT), 218
Prostatic intraepithelial neoplasia (PIN), 105
Prostatic needle biopsy (PNBX)
ATYP, 160–161
diagnostic categories, 155, 156
differential diagnosis, 160
fixative, 154
GS grading system (see Gleason score (GS) grading system)
HGPIN, 161–162
IHC marker, 156
morphological features, 155–156
PNI, 159–160
procedure, 153–154
slide preparation, 155
specimen submission, 154–155
tumor extent, 159
Prostatitis, 103, 104
Proton beam therapy, 244
PSA. See Prostate-specific antigen (PSA)
PUFAs. See Polyunsaturated fats (PUFAs)

R
Radiation therapy. See also External beam radiation therapy (EBRT)
with androgen deprivation therapy
Canadian RCT, 288
clinical outcomes, 286
EORTC 22863, 287
EORTC 22961, 288–291
optimal duration, 287
RTOG 85-31, 286
RTOG 86-10, 287
RTOG 92-02, 288
trans-tasman oncology group 96.01 rct, 287–288
dose-escalation trials (see dose-escalated radiation therapy)
technological advancements
3d-crt technology, 245
ebrt, 245
igrt, 245
imrt, 245
real-time tracking, 245
stereotactic body radiotherapy, 245–246
treatment planning
brachytherapy and supplemental ebrt, 246
ct simulation, 246
gross tumor volume, 246
mri and mr-spectroscopy, 246
planning target volume, 246
postoperative setting, 246–247
radical prostatectomy (rp), 263, 352–353
advanced clinical t stage, 276–278
cancer-specific survival, 271
GS 8–10 prostate cancers
AHT, 275
EBRT, 275
Mayo clinic study, 273–274
PSA testing of, 274
health-related quality-of-life, 308–309
high-risk prostate cancer
biochemical recurrence, 272
CapSURE database, 272
local recurrence-free survival, 273
long-term css control, 273
Mayo Clinic validation study, 272
MSKCC study, 273
surgical staging, 273
high serum PSA levels, 275–276
Kaplan–Meier estimate
biochemical relapse-free survival, 264
clinical relapse-free survival, 265
overall survival, 265, 266
specimens
embedding, 163–164
essential elements, 165
extraprostatic extension, 166–167
fixation, 162
Gleason score, 165
lymphovascular invasion, 169
pathologic staging, 170, 171
sectioning, 162–163
seminal vesicle invasion, 167
surgical margin of resection, 167–169
tumor multifocality, 165–166
tumor volume, 166
TURP and SP, 164
uses, 164
toxicity, 267, 268
urinary incontinence (see post-prostatectomy incontinence (PPI))
real-time elastography (RTE), 192
REDUCE trial, 148–149
remitex®, 331
rhenium 186 and rhenium 188, 415
RNASEL, 6, 8, 109
S
Samarium 153, 414–416
saturation prostate biopsy (sPBx)
active surveillance, 188–189
anterior horn, 186–187
cancer detection risk, 191
24-core transrectal template, 185
development, 185
initial biopsy strategy, 188
patient management after negative sPBx, 190–191
patient selection and focal therapy, 189–190
reduced sampling, 185, 186
repeat biopsy strategy, 187–188
safety and complications, 190
SEER. See surveillance, epidemiology, and end results (SEER)
selenium, 137, 149–150
Selenium and Vitamin E Cancer Prevention Trial (SELECT), 108, 149–150
Seminal vesicle invasion (Svi), 167
Serial biopsy, 218
Sex steroid hormones, 106–107, 131–132
Sexually transmitted diseases (STDs), 8
simple prostatectomy (sp), 164
single nucleotide polymorphisms (SNPs), 5
sipuleucel-T, CRPC, 405
SNPs. See Single nucleotide polymorphisms (SNPs)
Soy and isoflavones, 136–137
sPBx. See Saturation prostate biopsy (sPBx)
Sphincteric dysfunction, PPI
medical management
duloxetine, 327–328
phosphodiesterase type 5-inhibitors, 328
surgical management, 328
STDs. See Sexually transmitted diseases (STDs)
Stereotactic body radiotherapy (SBRT), 245–246
Strontium 89, 414–415
surveillance, epidemiology, and end results (SEER), 1, 3
T
three-dimensional conformal radiation therapy (3D-CRT), 245
tip-sparing prostatectomy, 323
toll-like receptor (TLR), 109
transcription-mediated amplification (tMA) assay, 61
analytical performance, 61–62
applications
low-grade cancer vs. significant cancer, 63–64
REDUCE trial, 62–63
radical prostatectomy patients, 61
transperineal prostate (TP) biopsy
advantages, 193
applications, 194–195
Transperineal prostate (TP) biopsy (cont.)
   24-core scheme, 195
   TR approach and, 193–194
Transrectal ultrasonography (TRUS), 16, 153
   CDUS, 191–192
   CECD, 192
   end-fire probes, 193, 194
   RTE, 192
   side-fire probes, 192–193
Transurethral resection of prostate (TURP), 153, 164
TRUS biopsy, 233
Tumor volume (TV), 166

U
Unilateral hemi-ablation model
   bDFS rates, 230
   extra-capsular extension, 230
   index tumor, 226–229
   Kaplan-Meier recurrence-free survival plots, 228, 229, 231
   lymph nodes metastases, 232
   PSA failure rates, 230
   satellite lesions, 232
   small-volume PCas, 230–231
   tumor volume, 231–232
   unilateral lesions frequency, 227
United States Preventive Services Task Force (USPSTF), 28–30
Urethral slings, PPI
   adjustable sling systems, 331, 332

V
Vasectomy, 9
Vitamins
   chemoprevention
      folate, 150
      vitamin E, 149–150
   vitamin D, 136
   vitamin E, 137, 149–150

W
WW oxidoreductase (WWOX), 82

X
Xenotropic murine leukemia virus related
   virus (XMRV), 8